Abadie, A. Using synthetic controls: feasibility, data requirements, and methodological aspects. 2021 J. Econ. Lit.. 59 391-425
Abadie, A. ; Diamond, A. ; Hainmueller, J. Comparative politics and the synthetic control method. 2015 Am. J. Polit. Sci.. 59 495-510
Abadie, A. ; Diamond, A. ; Hainmueller, J. Synthetic control methods for comparative case studies: estimating the effect of California’s tobacco control program. 2010 J. Am. Stat. Assoc.. 105 493-505
Abadie, A. ; Gardeazabal, J. The economic costs of conflict: a case study of the Basque Country. 2003 Am. Econ. Rev.. 93 113-132
Acemoglu, D. ; Linn, J. Market size in innovation: theory and evidence from the pharmaceutical industry*. 2004 Q. J. Econ.. 119 1049-1090
Álvarez-Ayuso, I.C. ; Kao, C. ; Romero-Jordán, D. Long run effect of public grants and tax credits on R&D investment: a non-stationary panel data approach. 2018 Econ. Model.. 75 93-104
Athey, S. ; Imbens, G.W. The state of applied econometrics: causality and policy evaluation. 2017 J. Econ. Perspect.. 31 3-32
Banal-Estañol, A. ; Jofre-Bonet, M. ; Iori, G. ; Maynou, L. ; Tumminello, M. ; Vassallo, P. Performance-based research funding: evidence from the largest natural experiment worldwide. 2023 Res. Policy. 52 -
Bloom, N. ; Griffith, R. ; Van Reenen, J. Do R&D tax credits work? Evidence from a panel of countries 1979–1997. 2002 J. Public Econ.. 85 1-31
- Blume-Kohout, M.E. Does targeted, disease-specific public research funding influence pharmaceutical innovation?. 2012 J. Policy Anal. Manage.. 31 641-660
Paper not yet in RePEc: Add citation now
- Bouttell, J. ; Craig, P. ; Lewsey, J. ; Robinson, M. ; Popham, F. Synthetic control methodology as a tool for evaluating population-level health interventions. 2018 J. Epidemiol. Community Health. 72 673-678
Paper not yet in RePEc: Add citation now
Brassel, S. ; Cookson, G. Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-based Policies. 2020 Office of Health Economics:
Cavallo, E. ; Galiani, S. ; Noy, I. ; Pantano, J. Catastrophic natural disasters and economic growth. 2013 Rev. Econ. Stat.. 95 1549-1561
Chang, A.C. Tax policy endogeneity: evidence from R&D tax credits. 2018 Econ. Innov. New Technol.. 27 809-833
Chen, S.-S. ; Kao, W.-C. ; Wang, Y. Tax policy and innovation performance: evidence from enactment of the alternative simplified credit. 2021 J. Bank. Financ.. 125 -
Coad, A. Persistent heterogeneity of R&D intensities within sectors: evidence and policy implications. 2019 Res. Policy. 48 37-50
- Cunningham, S. Causal Inference. [online]. 2021 Yale University Press:
Paper not yet in RePEc: Add citation now
David, P.A. ; Hall, B.H. ; Toole, A.A. Is public R&D a complement or substitute for private R&D? A review of the econometric evidence. 2000 Res. Policy. 29 497-529
- DiMasi, J.A. ; Grabowski, H.G. R&d costs and returns to new DRUG DEVELOPMENT: A review of the evidence. 2012 En : The Oxford Handbook of the Economics of the Biopharmaceutical Industry. Oxford University Press:
Paper not yet in RePEc: Add citation now
DiMasi, J.A. ; Grabowski, H.G. ; Hansen, R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs. 2016 J. Health Econ.. 47 20-33
Dubois, P. ; Mouzon, O. de ; Scott-Morton, F. ; Seabright, P. Market size and pharmaceutical innovation. 2015 RAND J. Econ.. 46 844-871
Finkelstein, A. Static and dynamic effects of health policy: evidence from the vaccine industry*. 2004 Q. J. Econ.. 119 527-564
- Fowkes, R.K. ; Sousa, J. ; Duncan, N. Evaluation of Research and Development Tax Credit. [online]. 2015 HMRC:
Paper not yet in RePEc: Add citation now
Hall, B. ; Van Reenen, J. How effective are fiscal incentives for R&D? A review of the evidence. 2000 Res. Policy. 29 449-469
- HM Revenue & Customs, Claim Research and Development (R&D) Expenditure Credit. [online]. 2021 GOV.UK:
Paper not yet in RePEc: Add citation now
- IFPMA, Facts and Figures 2021: The Pharmaceutical Industry and Global Health. [online]. 2021 IFPMA:
Paper not yet in RePEc: Add citation now
- Kennedy, J. How to Ensure That America’s Life-Sciences Sector Remains Globally Competitive. [online]. 2018 Information Technology and Innovation Foundation:
Paper not yet in RePEc: Add citation now
- Koga, T. Firm size and R&D tax incentives. 2003 Technovation. 23 643-648
Paper not yet in RePEc: Add citation now
Kourouklis, D. Public subsidies for R&D and public sector pharmaceutical innovation. 2021 Appl. Econ.. 53 3759-3777
Kourouklis, D. ; Gandjour, A. Pharmaceutical spending and early-stage innovation in EU countries. 2022 Ind. Innov.. 29 1141-1170
Kreif, N. ; Grieve, R. ; Hangartner, D. ; Turner, A.J. ; Nikolova, S. ; Sutton, M. Examination of the synthetic control method for evaluating health policies with multiple treated units. 2016 Health Econ.. 25 1514-1528
Krieger, J. ; Li, D. ; Papanikolaou, D. Missing novelty in drug development. 2022 Rev. Financ. Stud.. 35 636-679
Krieger, J.L. Trials and terminations: learning from competitors’ R&D failures. 2021 Manag. Sci.. 67 5525-5548
Lee, D. Impact of the excise tax on firm R&D and performance in the medical device industry: evidence from the Affordable Care Act. 2018 Res. Policy. 47 854-871
- Lichtenberg, F.R. The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998-2017. 2021 Expert Rev. Pharmacoecon. Outcomes Res.. 0 -
Paper not yet in RePEc: Add citation now
- Martin, B.R. R&D policy instruments – a critical review of what we do and don’t know. 2016 Ind. Innov.. 23 157-176
Paper not yet in RePEc: Add citation now
- McCutchen, W.W. Estimating the impact of the R&D tax credit on strategic groups in the pharmaceutical industry. 1993 Res. Policy. 22 337-351
Paper not yet in RePEc: Add citation now
Minniti, A. ; Venturini, F. The long-run growth effects of R&D policy. 2017 Res. Policy. 46 316-326
- Morris, S. ; Devlin, N. ; Parkin, D. ; Spencer, A. Economic Analysis in Healthcare. 2012 Wiley:
Paper not yet in RePEc: Add citation now
Mueller-Langer, F. Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?. 2013 Health Econ. Policy Law. 8 185-208
- OECD, OECD Science, Technology and Innovation Outlook 2023: Enabling Transitions in Times of Disruption. 2023 OECD Science, Technology and Innovation Outlook:
Paper not yet in RePEc: Add citation now
- OECD, 2021a. Elderly Population (Indicator). [online] Available at: https://doi.org/10.1787/8d805ea1-en [Accessed 29 Oct. 2021].
Paper not yet in RePEc: Add citation now
Olson, M.K. ; Yin, N. Examining firm responses to R&D policy: an analysis of pediatric exclusivity. 2018 American Journal of Health Economics. 4 321-357
Paff, L.A. State-level R&D tax credits: a firm-level analysis. 2005 The B.E. Journal of Economic Analysis & Policy. 5 -
- Prasad, V. ; Mailankody, S. Research and development spending to bring a single cancer drug to market and revenues after approval. 2017 JAMA Intern Med.. 177 1569-1575
Paper not yet in RePEc: Add citation now
Rao, N. Do tax credits stimulate R&D spending? The effect of the R&D tax credit in its first decade. 2016 J. Public Econ.. 140 1-12
- Renwick, M.J. ; Brogan, D.M. ; Mossialos, E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. 2016 J. Antibiot.. 69 73-88
Paper not yet in RePEc: Add citation now
- Scannell, J.W. ; Blanckley, A. ; Boldon, H. ; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. 2012 Nat. Rev. Drug Discov.. 11 191-200
Paper not yet in RePEc: Add citation now
- Scott Morton, F. ; Kyle, M. Chapter Twelve - Markets for Pharmaceutical Products11The authors thank Tom McGuire for editorial advice and improvements and participants at the Handbook conference for helpful suggestions. 2011 En : Pauly, M.V. ; Mcguire, T.G. ; Barros, P.P. Handbook of Health Economics, Handbook of Health Economics. Elsevier:
Paper not yet in RePEc: Add citation now
- Tragner, J. Research and Development Expenditure Credit Scheme Explained. 2017 ForrestBrown:
Paper not yet in RePEc: Add citation now
- Turner, M. Vaccine procurement during an influenza pandemic and the role of Advance Purchase Agreements: lessons from 2009-H1N1. 2016 Glob. Public Health. 11 322-335
Paper not yet in RePEc: Add citation now
- Venugopal, N. ; Saberwal, G. A comparative analysis of important public clinical trial registries, and a proposal for an interim ideal one. 2021 PLoS One. 16 -
Paper not yet in RePEc: Add citation now
von Brasch, T. ; Cappelen, Å. ; Hungnes, H. ; Skjerpen, T. Modeling R&D spillovers to productivity: the effects of tax credits. 2021 Econ. Model.. 101 -
- Wouters, O.J. ; McKee, M. ; Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. 2020 JAMA. 323 844-853
Paper not yet in RePEc: Add citation now
Yang, C.-H. ; Huang, C.-H. ; Hou, T.C.-T. Tax incentives and R&D activity: firm-level evidence from Taiwan. 2012 Res. Policy. 41 1578-1588
Yin, W. Market incentives and pharmaceutical innovation. 2008 J. Health Econ.. 27 1060-1077